Zai Lab Limited (ZLAB) Stock Jumps 6.8%: Will It Continue to Soar?

By Zacks Equity Research | July 23, 2025, 9:57 AM

Vertex Pharmaceuticals Inc

Zai Lab Limited ADR

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Zai Lab Limited Unsponsored ADR (ZLAB): Free Stock Analysis Report

Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Mentioned In This Article

Vertex Pharmaceuticals Inc

Zai Lab Limited ADR

Latest News

Apr-22	Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026 ZLAB -6.42% Business Wire
Apr-18	Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31R Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases ZLAB Business Wire
Apr-17	Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas ZLAB Business Wire
Apr-16	Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study ZLAB Pharmaceutical Business Review
Apr-10	Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells VRTX PR Newswire
Apr-08	Novo underprices Lilly with higher-dose Wegovy; Insmed absorbs expected study failure VRTX BioPharma Dive
Apr-08	Halozyme and Vertex sign deal for Hypercon technology VRTX Pharmaceutical Technology
Apr-06	Vertex to Announce First Quarter 2026 Financial Results on May 4th VRTX Business Wire
Apr-01	Vertex Announces US FDA Approval for Label Extensions of ALYFTREK and TRIKAFTA, Expanding Availability of These Medicines to ~95% of All People With CF in the United States VRTX Business Wire
Apr-01	Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy ZLAB +8.13% Business Wire
Mar-28	What are U.S. companies doing with cash? VRTX Investing.com
Mar-25	Maze set to target Vertex as kidney disease drug succeeds in Phase II trial VRTX Clinical Trials Arena
Mar-25	Maze tumbles despite positive data for kidney disease drug VRTX BioPharma Dive
Mar-25	Maze tumbles on positive data for kidney disease drug VRTX BioPharma Dive
Mar-25	Why Maze Therapeutics Plunged 20%-Plus Despite 'Overwhelming Positive' Data VRTX Investor's Business Daily

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)